NASDAQ: TERN
Terns Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for TERN

Based on 4 analysts offering 12 month price targets for Terns Pharmaceuticals Inc

Min Forecast
$7.44-8.82%
Avg Forecast
$14.11+72.92%
Max Forecast
$20.00+145.1%

Should I buy or sell TERN stock?

Based on 4 analysts offering ratings for Terns Pharmaceuticals Inc.

Strong Buy
Strong Buy
2 analysts 50%
Buy
1 analysts 25%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TERN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TERN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their TERN stock forecasts and price targets.

TERN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-23
lockedlocked$00.00+00.00%2025-10-22
lockedlocked$00.00+00.00%2025-10-15
lockedlocked$00.00+00.00%2025-09-04

1 of 1

Forecast return on equity

Is TERN forecast to generate an efficient return?

Company
-40.21%
Industry
252.89%
Market
145.2%
TERN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TERN forecast to generate an efficient return on assets?

Company
-38.3%
Industry
107.15%
TERN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TERN earnings per share forecast

What is TERN's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
-$1.15
Avg 2 year Forecast
-$1.37
Avg 3 year Forecast
-$1.59

TERN revenue forecast

What is TERN's revenue in the next 3 years based on estimates from 12 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

TERN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TERN$8.16$14.11+72.92%Strong Buy
TBPH$14.30$25.67+79.49%Strong Buy
DAWN$7.04$20.50+191.19%Buy
ATXS$12.51$28.00+123.82%Buy
IOVA$1.95$9.57+390.82%Strong Buy

Terns Pharmaceuticals Stock Forecast FAQ

Is Terns Pharmaceuticals Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: TERN) stock is to Strong Buy TERN stock.

Out of 4 analysts, 2 (50%) are recommending TERN as a Strong Buy, 1 (25%) are recommending TERN as a Buy, 1 (25%) are recommending TERN as a Hold, 0 (0%) are recommending TERN as a Sell, and 0 (0%) are recommending TERN as a Strong Sell.

If you're new to stock investing, here's how to buy Terns Pharmaceuticals stock.

What is TERN's earnings growth forecast for 2025-2027?

(NASDAQ: TERN) Terns Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.35%.

Terns Pharmaceuticals's earnings in 2025 is -$91,745,000.On average, 14 Wall Street analysts forecast TERN's earnings for 2025 to be -$100,550,194, with the lowest TERN earnings forecast at -$107,201,034, and the highest TERN earnings forecast at -$97,399,796. On average, 13 Wall Street analysts forecast TERN's earnings for 2026 to be -$119,680,109, with the lowest TERN earnings forecast at -$140,647,756, and the highest TERN earnings forecast at -$103,831,858.

In 2027, TERN is forecast to generate -$138,915,038 in earnings, with the lowest earnings forecast at -$158,657,530 and the highest earnings forecast at -$124,965,777.

What is TERN's revenue growth forecast for 2025-2027?

(NASDAQ: TERN) Terns Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.08%.

Terns Pharmaceuticals's revenue in 2025 is $0.On average, 12 Wall Street analysts forecast TERN's revenue for 2025 to be $0, with the lowest TERN revenue forecast at $0, and the highest TERN revenue forecast at $0. On average, 12 Wall Street analysts forecast TERN's revenue for 2026 to be $0, with the lowest TERN revenue forecast at $0, and the highest TERN revenue forecast at $0.

In 2027, TERN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is TERN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TERN) forecast ROA is -38.3%, which is lower than the forecast US Biotechnology industry average of 107.15%.

What is TERN's Price Target?

According to 4 Wall Street analysts that have issued a 1 year TERN price target, the average TERN price target is $14.11, with the highest TERN stock price forecast at $20.00 and the lowest TERN stock price forecast at $7.44.

On average, Wall Street analysts predict that Terns Pharmaceuticals's share price could reach $14.11 by Oct 23, 2026. The average Terns Pharmaceuticals stock price prediction forecasts a potential upside of 72.92% from the current TERN share price of $8.16.

What is TERN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TERN) Terns Pharmaceuticals's current Earnings Per Share (EPS) is -$1.03. On average, analysts forecast that TERN's EPS will be -$1.15 for 2025, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$1.11. On average, analysts forecast that TERN's EPS will be -$1.37 for 2026, with the lowest EPS forecast at -$1.61, and the highest EPS forecast at -$1.19. In 2027, TERN's EPS is forecast to hit -$1.59 (min: -$1.81, max: -$1.43).

What is TERN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TERN) forecast ROE is -40.21%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.